Trial tests new combination of drugs to treat tuberculosis

BMJ 2012; 344 doi: (Published 20 March 2012) Cite this as: BMJ 2012;344:e2216
  1. Bob Roehr
  1. 1Washington, DC

The Global Alliance for TB Drug Development (TB Alliance) has launched a first of its kind clinical trial of a new drug combination that is enrolling patients with drug sensitive or multidrug resistant tuberculosis.

The trial is a milestone in the process of revitalising all phases of tuberculosis research—from basic pathology to diagnostics, new drugs, and vaccines—that began a decade ago, said Mel Spigelman, president of the TB Alliance, at a forum in Washington, DC, in advance of world TB day on 24 March. The alliance is a collaboration of drug companies, government agencies, and charities.

To elicit a response in people with drug resistant tuberculosis, doctors have often added a …

View Full Text

Log in

Log in through your institution


* For online subscription